 SAN DIEGO, Aug. 5, 2021 PRNewswire -- Neurocrine Biosciences, Inc. Nasdaq: NBIX, in collaboration with the Huntington Study Group, today announced the completion of patient enrollment for its Phase 3 KINECT-HD clinical study evaluating the efficacy, safety and tolerability of valbenazine, a selective, orally active vesicular monoamine transporter 2 VMAT2 inhibitor being investigated as a once-daily treatment in adults with chorea in Huntington disease. A top-line data readout of the clinical study results is anticipated by the end of 2021. 